HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response

Cancer Immunology, Immunotherapy

Volumn 61, Issue 1, 2012, Pages 31-40

  Codolo, Gaia ^a,b   Fassan, Matteo ^a   Munari, Fabio ^a,b   Volpe, Andrea ^c   Bassi, Piefrancesco ^c   Rugge, Massimo ^a,d   Pagano, Francesco ^b   D'Elios, Mario Milco ^e   De Bernard, Marina ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Bladder cancer; HP NAP; Immunotherapy; Th1 response

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; GAMMA INTERFERON; PROTEIN HP NAP; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR NECROSIS;

ADMINISTRATION, INTRAVESICAL; ANIMALS; BACTERIAL PROTEINS; BCG VACCINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HELICOBACTER PYLORI; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; TH1 CELLS; URINARY BLADDER NEOPLASMS;

EID: 84856699979     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1087-2     Document Type: Article

References (20)

1. A Jemal, et al. 2010 Cancer statistics CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
2. SS Devesa, et al. 1995 Recent cancer trends in the united states J Natl Cancer Inst 87 3 175 182 7707404 10.1093/jnci/87.3.175 1:STN:280: DyaK2M3it1Khsw%3D%3D
3. MS Soloway 1988 Introduction and overview of intravesical therapy for superficial bladder cancer Urology 31 3 Suppl 5 16 3126593 1:STN:280: DyaL1c7lvF2mtQ%3D%3D (Pubitemid 18086590)
4. Y Hasui, et al. 1994 Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer Urology 43 6 782 786 8197643 10.1016/0090-4295(94)90134-1 1:STN:280:DyaK2c3lsF2ksg%3D%3D (Pubitemid 24174465)
5. F Saint, et al. 2002 Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer J Urol 167 1 364 367 11743357 10.1016/S0022-5347(05)65469-9 (Pubitemid 34024586)
6. O Shahin, et al. 2003 A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 1 96 100 12478112 10.1016/S0022-5347(05)64044-X 1:CAS:528:DC%2BD38XpsVGksLc%3D discussion 100 (Pubitemid 35461560)
7. DL Lamm 1992 Complications of bacillus Calmette-Guerin immunotherapy Urol Clin North Am 19 3 565 572 1636240 1:STN:280:DyaK38zktlWhuw%3D%3D
8. R De Jager, et al. 1991 Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials Urology 38 6 507 513 1836081 10.1016/0090-4295(91) 80166-5
9. MP Colombo G Trinchieri 2002 Interleukin-12 in anti-tumor immunity and immunotherapy Cytokine Growth Factor Rev 13 2 155 168 11900991 10.1016/S1359-6101(01)00032-6 1:CAS:528:DC%2BD38XitFWhs74%3D (Pubitemid 34229390)
10. MA Cheever 2008 Twelve immunotherapy drugs that could cure cancers Immunol Rev 222 357 368 18364014 10.1111/j.1600-065X.2008.00604.x 1:CAS:528:DC%2BD1cXlsFejtLo%3D (Pubitemid 351430366)
11. JP Leonard, et al. 1997 Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 90 7 2541 2548 9326219 1:CAS:528:DyaK2sXmtlegtrg%3D (Pubitemid 27413462)
12. DA Zaharoff, et al. 2009 Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Res 69 15 6192 6199 19638573 10.1158/0008-5472.CAN-09-1114 1:CAS:528:DC%2BD1MXpt1Cgtb0%3D
13. A Amedei, et al. 2006 The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses J Clin Invest 116 4 1092 1101 16543949 10.1172/JCI27177 1:CAS:528:DC%2BD28XjsVWnurg%3D
14. de Bernard M, D'Elios MM (2009) The immune modulating activity of the Helicobacter pylori HP-NAP: Friend or foe? Toxicon 56:1186-1192
15. G Codolo, et al. 2008 The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma Cell Microbiol 10 11 2355 2363 18671823 10.1111/j.1462-5822.2008.01217.x 1:CAS:528:DC%2BD1cXhtlyru7%2FL
16. JM Wigginton, et al. 2001 IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy J Clin Invest 108 1 51 62 11435457 1:CAS:528:DC%2BD3MXkvVars70%3D (Pubitemid 32634922)
17. O Takeuchi, et al. 1999 Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components Immunity 11 4 443 451 10549626 10.1016/S1074-7613(00)80119-3 1:CAS:528:DyaK1MXntFCnur4%3D (Pubitemid 29504199)
18. N Weidner, et al. 1993 Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 2 401 409 7688183 1:STN:280:DyaK3szktlWqtQ%3D%3D (Pubitemid 24058195)
19. JH Gunther, et al. 1999 Optimizing syngeneic orthotopic murine bladder cancer (MB49) Cancer Res 59 12 2834 2837 10383142 1:CAS:528:DyaK1MXktVOku74%3D (Pubitemid 29283119)
20. MM D'Elios, et al. 1997 T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease J Immunol 158 2 962 967 8993017 (Pubitemid 127492677)